Eun Shin

Dr. Eun Shin

orcid

Research Focus & Metrics

Academic Career Length

20Years (2007-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 September 2018 in Gastroenterology
Verified
Journal Article
Closed access
PDF file
MCMarcia Irene Canto
Marcia Irene Canto
JAJose Alejandro Almario
Jose Alejandro Almario
RSRichard D. Schulick
Richard D. Schulick
CYCharles J. Yeo
Charles J. Yeo
AKAlison Klein
Alison Klein
MGMichael Goggins
Michael Goggins

15 June 2022 in Journal of Clinical Oncology
Verified
Journal Article
Open access
MDMohamad Dbouk
Mohamad Dbouk
BKBryson W Katona
Bryson W Katona
RBRandall E. Brand
Randall E. Brand
ACAmitabh Chak
Amitabh Chak
SSSapna Syngal
Sapna Syngal
MGMichael Goggins
Michael Goggins
PURPOSE: To report pancreas surveillance outcomes of high-risk individuals within the multicenter Cancer of Pancreas Screening-5 (CAPS5) study and to update outcomes of patients enrolled in prior CAPS studies. METHODS: Individuals recommended for pancreas surveillance were prospectively enrolled into one of eight CAPS5 study centers between 2014 and 2021. The primary end point was the stage distribution of pancreatic ductal adenocarcinoma (PDAC) detected (stage I v higher-stage). Overall survival was determined using the Kaplan-Meier method. RESULTS: Of 1,461 high-risk individuals enrolled into CAPS5, 48.5% had a pathogenic variant in a PDAC-susceptibility gene. Ten patients were diagnosed with PDAC, one of whom was diagnosed with metastatic PDAC 4 years after dropping out of surveillance. Of the remaining nine, seven (77.8%) had a stage I PDAC (by surgical pathology) detected during surveillance; one had stage II, and one had stage III disease. Seven of these nine patients with PDAC were alive after a median follow-up of 2.6 years. Eight additional patients underwent surgical resection for worrisome lesions; three had high-grade and five had low-grade dysplasia in their resected specimens. In the entire CAPS cohort (CAPS1-5 studies, 1,731 patients), 26 PDAC cases have been diagnosed, 19 within surveillance, 57.9% of whom had stage I and 5.2% had stage IV disease. By contrast, six of the seven PDACs (85.7%) detected outside surveillance were stage IV. Five-year survival to date of the patients with a screen-detected PDAC is 73.3%, and median overall survival is 9.8 years, compared with 1.5 years for patients diagnosed with PDAC outside surveillance (hazard ratio [95% CI]; 0.13 [0.03 to 0.50], P = .003). CONCLUSION: Most pancreatic cancers diagnosed within the CAPS high-risk cohort in the recent years have had stage I disease with long-term survival.

4 February 2014 in Hepatology
Verified
Journal Article
Open access
PDF file
LLLing Li
Ling Li
DMDavid Masica
David Masica
MIMasaharu Ishida
Masaharu Ishida
CTCiprian Tomuleasa
Ciprian Tomuleasa
SUSho Umegaki
Sho Umegaki
FSFlorin M. Selaru
Florin M. Selaru
Cholangiocarcinoma (CCA) presents significant diagnostic challenges, resulting in late patient diagnosis and poor survival rates. Primary sclerosing cholangitis (PSC) patients pose a particularly difficult clinical dilemma because they harbor chronic biliary strictures that are difficult to distinguish from CCA. MicroRNAs (miRs) have recently emerged as a valuable class of diagnostic markers; however, thus far, neither extracellular vesicles (EVs) nor miRs within EVs have been investigated in human bile. We aimed to comprehensively characterize human biliary EVs, including their miR content. We have established the presence of extracellular vesicles in human bile. In addition, we have demonstrated that human biliary EVs contain abundant miR species, which are stable and therefore amenable to the development of disease marker panels. Furthermore, we have characterized the protein content, size, numbers, and size distribution of human biliary EVs. Utilizing multivariate organization of combinatorial alterations (MOCA), we defined a novel biliary vesicle miR-based panel for CCA diagnosis that demonstrated a sensitivity of 67% and specificity of 96%. Importantly, our control group contained 13 PSC patients, 16 with biliary obstruction of varying etiologies (including benign biliary stricture, papillary stenosis, choledocholithiasis, extrinsic compression from pancreatic cysts, and cholangitis), and 3 with bile leak syndromes. Clinically, these types of patients present with a biliary obstructive clinical picture that could be confused with CCA. Conclusion: These findings establish the importance of using extracellular vesicles, rather than whole bile, for developing miR-based disease markers in bile. Finally, we report on the development of a novel bile-based CCA diagnostic panel that is stable, reproducible, and has potential clinical utility. (Hepatology 2014;60:896–907)

1 June 2019 in Radiology
Verified
Journal Article
Open access
CWClifford Raabe Weiss
Clifford Raabe Weiss
GAGodwin O. Abiola
Godwin O. Abiola
AFAaron Fischman
Aaron Fischman
LCLawrence Cheskin
Lawrence Cheskin
JVJay Vairavamurthy
Jay Vairavamurthy
AAAravind Arepally
Aravind Arepally
Bariatric embolization is a feasible and well-tolerated procedure that produces weight loss and reduces appetite for up to 1 year. Background Bariatric embolization is a new endovascular procedure to treat patients with obesity. However, the safety and efficacy of bariatric embolization are unknown. Purpose To evaluate the saf...

1 April 2021 in Pancreatology
Verified
Journal Article
Closed access
MDMohamad Dbouk
Mohamad Dbouk
OGOlaya I. Brewer Gutierrez
Olaya I. Brewer Gutierrez
ALAnne Marie Lennon
Anne Marie Lennon
MCMiguel Chuidian
Miguel Chuidian
ESEun Shin
Eun Shin
MCMarcia Irene Canto
Marcia Irene Canto

30 November 2022 in Science Translational Medicine
Verified
Journal Article
Closed access
HZHua Zhao
Hua Zhao
YCYulan Cheng
Yulan Cheng
AKAndrew Kalra
Andrew Kalra
KMKe Ma
Ke Ma
YZYueyuan Zheng
Yueyuan Zheng
SMStephen J. Meltzer
Stephen J. Meltzer
Inactivation of the tumor suppressor genes tumor protein p53 (TP53) and cyclin-dependent kinase inhibitor 2A (CDKN2A) occurs early during gastroesophageal junction (GEJ) tumorigenesis. However, because of a paucity of GEJ-specific disease models, cancer-promoting consequences ofTP53andCDKN2Ainactivation at the GEJ have not been characterized. Here, we report the development of a wild-type primary human GEJ organoid model and a CRISPR-edited transformed GEJ organoid model. CRISPR-Cas9–mediatedTP53andCDKN2Aknockout (TP53/CDKN2AKO) in GEJ organoids induced morphologic dysplasia and proneoplastic features in vitro and tumor formation in vivo. Lipidomic profiling identified several platelet-activating factors (PTAFs) among the most up-regulated lipids in CRISPR-edited organoids. PTAF/PTAF receptor (PTAFR) abrogation by siRNA knockdown or a pharmacologic inhibitor (WEB2086) reduced proliferation and other proneoplastic features ofTP53/CDKN2AKOGEJ organoids in vitro and tumor formation in vivo. In addition, murine xenografts of Eso26, an established human esophageal adenocarcinoma cell line, were suppressed by WEB2086. Mechanistically,TP53/CDKN2Adual inactivation disrupted both the transcriptome and the DNA methylome, likely mediated by key transcription factors, particularly forkhead box M1 (FOXM1). FOXM1 activatedPTAFRtranscription by binding to thePTAFRpromoter, further amplifying the PTAF-PTAFR pathway. Together, these studies established a robust model system for investigating early GEJ neoplastic events, identified crucial metabolic and epigenomic changes occurring during GEJ model tumorigenesis, and revealed a potential cancer therapeutic strategy. This work provides insights into proneoplastic mechanisms associated withTP53/CDKN2Ainactivation in early GEJ neoplasia, which may facilitate early diagnosis and prevention of GEJ neoplasms.